Effects of a novel anti-hyperlipidemic agent, S-2e, on blood lipid levels in rats with fructose-induced hypertriglyceridemia

Pharmacology

Volumn 72, Issue 4, 2004, Pages 240-246

  Ohmori, Koichi ^a   Yamada, Haruo ^a   Yasuda, Akio ^a   Yamamoto, Akira ^a   Matsuura, Naosuke ^a   Kiniwa, Mamoru ^a  

^a TAIHO PHARMACEUTICAL CO LTD   (Japan)

Author keywords

(+) (S) p 1 (p tert butylphenyl) 2 oxo 4 pyrrolidinyl methoxybenzoic acid; Fructose induced hypertriglyceridemia; High density lipoprotein cholesterol elevation; Very low density lipoprotein production

Indexed keywords

4 [1 (4 TERT BUTYLPHENYL) 2 OXO 4 PYRROLIDINYL]METHOXYBENZOIC ACID; ANTILIPEMIC AGENT; BENZOIC ACID DERIVATIVE; BEZAFIBRATE; FRUCTOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; S 2E; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DOSE RESPONSE; FEEDING; HYPERTRIGLYCERIDEMIA; LIPID BLOOD LEVEL; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; TRIACYLGLYCEROL BLOOD LEVEL;

ANIMALS; ANTILIPEMIC AGENTS; BENZOIC ACIDS; BEZAFIBRATE; CHOLESTEROL; CHOLESTEROL, HDL; DIET; FRUCTOSE; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; LIPID METABOLISM; LIPIDS; LIVER; MALE; PYRROLIDINONES; RATS; RATS, SPRAGUE-DAWLEY; TRIGLYCERIDES;

EID: 8344233541     PISSN: 00317012     EISSN: None     Source Type: Journal    
DOI: 10.1159/000080379     Document Type: Article

References (31)

1. Durrington PN: Diabetic dyslipidemia. Baillères Clin Endocrinol Metab 1999;13:265-278.
2. Fruchart JC, Duriez P: HDL and triglyceride as therapeutic targets. Curr Opin Lipidol 2002;13:605-616.
3. Lamarche B, Rashid S, Lewis GF: HDL metabolism in hypertriglyceridemic states: An overview. Clin Chim Acta 1999;286:145-161.
4. Adeli A, Taghibiglou C, van Iderstine SC, Lewis GF: Mechanisms of hepatic very low-density lipoprotein overproduction in insulin resistance. Trends Cardiovasc Med 2001;11:170-176.
5. Taskinen MR: Insulin resistance and lipoprotein metabolism. Curr Opin Lipidol 1995;6:153-160.
6. Kobayashi J, Takahashi K, Tashiro J, Saito Y, Yoshida S, Hashimoto H, Fukamachi I, Niihara N, Sasaki N: Effects of treatment with bezafibrate on lipoprotein lipase activity and mass in patients with hypertriglyceridemia. Drug Res 1994;44:145-148.
7. Barter PJ, Brewer HB, Chapman MJ, Hennekens CH, Rader DJ, Tal AR: Cholesteryl ester transfer protein: A novel target for raising HDL and inhibiting atherosclerosis. Arterioscler Thromb Vasc Biol 2003;23:160-167.
8. Guerin M, Lassel TS, le Goff W, Farnier M, Chapman MJ: Action of atorvastatin in combined hyperlipidemia: Preferential reduction of cholesteryl ester transfer from HDL to VLDL1 particles. Arterioscler Thromb Vasc Biol 2000;20:189-197.
9. Okamoto H, Yonemori F, Wakitani K, Minowa T, Maeda K, Shikai H: A cholesteryl ester transfer protein inhibitor attenuates athrosclerosis in rabbits. Nature 2000;406:203-207.
10. Ohmori K, Yamada H, Yasuda A, Yamamoto A, Matsuura N, Kiniwa M: Anti-hyperlipidemic action of a newly synthesized benzoic acid derivative, S-2E. Eur J Pharmacol 2003;471:69-76.
11. Ohmori K, Yamada H, Yasuda A, Yamamoto A, Matsuura N, Kiniwa M: Effects of a novel anti-hyperlipidemic agent, S-2E, on the blood lipid abnormalities in homozygous WHHL rabbits. Metabolism 2004;53:680-685.
12. Zavaroni I, Chem YDI, Reaven GM: Studies of the mechanism of fructose-induced hypertriglyceridemia in the rat. Metabolism 1982;31:1077-1083.
13. Hwang IS, Ho H, Hoffman BB, Reaven GM: Fructose-induced insulin resistance and hypertension in rats. Hypertension 1987;10:512-516.
14. Thorburn AW, Storlien LH, Jenkins AB, Khouri S, Kraegen EW: Fructose-induced in vivo insulin resistance and elevated plasma triglyceride levels in rats. Am J Clin Nutr 1989;49:1155-1163.
15. Aoyama Y, Hattori Y, Yoshida A, Ashida K: Effect of glucose and fructose in a diet or drinking water on body weight gain, liver lipid content and serum triglyceride level in 4 strains of rats. Nutr Rep Int 1980;22:801-810.
16. Folch J, Lee M, Saloane-Stanley GA: A simple method for the isolation and purification of total lipids from animal tissues. J Biol Chem 1957;226:497-509.
17. Wanner C, Krane V: Non-high-density lipoprotein cholesterol: A target of lipid-lowering in dialysis patients. Am J Kidney Dis 2003;41:S72-S75.
18. Kusama H, Nishiyama M, Ikeda S: Pharmacological investigation of bezafibrate, a hypolipidemic agent (1). Effects of bezafibrate on normal and experimental hyperlipidemia in rats. Folia Pharmacol Jpn 1988;92:175-180.
19. Roglans N, Sanguino E, Peris C, Alegret M, Nazquez M, Adzet T, Diaz C, Hernandez G, Laguna JC, Sanchez RM: Atorvastatin treatment induced peroxisome proliferator-activated receptor alpha expression and decreased plasma nonesterified fatty acids and liver triglyceride in fructose-fed rats. J Pharmacol Exp Ther 2002;302:232-239.
20. Wetterau JR, Gregg RE, Harrity TW, Arbeeby C, Cap M, Connolly F, Chu CH, Geroge R, Gordon JDA, Jamil H, Jolibis KG, Kunselman LK, Lan SJ, Maccagnan TJ, Ricci B, Yan M, Young D, Chen Y, Fryszman O, Logan JVH, Musial CL, Poss MA, Robl JA, Simpkins LM, Slusararchyk WA, Sulsky R, Taunk P, Mahnin DR, Tino JA, Lawrence RM, Dikson JK Jr, Biller SA: An MTP inhibitor that normalizes atherogenic lipoprotein levels in WHHL rabbits. Science 1998;282:751-754.
21. Shiomi M, Ito T: MTP inhibitor decreases plasma cholesterol levels in LDL receptor-deficient WHHL rabbits by lowering the VLDL secretion. Eur J Pharmacol 2001;431:127-131.
22. Taghibiglou C, Carpentier A, van Iderstine SC, Chen, B, Rudy D, Airton A, Lewis GF, Adeli K: Mechanisms of hepatic very low-density lipoprotein overproduction in insulin resistance. J Biol Chem 2000;275:8416-8425.
23. Ohno T, Yano S, Yamada H, Shirasaka T, Yamamoto A, Kobayashi K, Ogawa K: Synthesis of the optical isomers of 4-[1-(4-tert-butylphenyl)-2-oxo-4- pyrrolidine-4-yl] methyloxybenzoic acids (S-2) and their biological evaluation as antilipidemic agent. Chem Pharm Bull 1999;47:1549-1554.
24. Remillard P, Shen G, Milne R, Maheux P: Induction of cholesteryl ester transfer protein in adipose tissue and plasma of the fructose-fed hamster. Life Sci 2001;69:677-687.
25. Wang IK, Lin-Shiau SY, Chen PC, Lin JK: Hypotriglyceridemic effect of Anka (a fermented rice product of Manascus sp.) in rats. J Agric Food Chem 2000;48:3183-3189.
26. Staels B, Dallongeville J, Auwerx J, Schoonjans K, Leitersdorf E, Fruchart JC: Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 1998;98:2088-2093.
27. Linton MF, Fazio S: Re-emergence of fibrates in the management of dyslipidemia and cardiovascular risk. Curr Atheroscler Rep 2000;2:29-35.
28. Okamoto KH, Iwamoto Y, Maki M, Sotani T, Yonemori F, Wakitani K: Effect of JTT-705 on cholesteryl ester transfer protein and plasma lipid levels in normolipidemic animals. Eur J Pharamacol 2003;446:147-154.
29. Guerin MG, Dolphin PJ, Turpin GT, Chapman MJ: Fenofibrate reduces plasma cholesteryl ester transfer from HDL to VLDL and normalizes the atherogenic, dense LDL profile in combined hyperlipidemia. Arterioscler Thromb Vasc Biol 1996;16:763-772.
30. Tsutsumi K, Hagi A, Inoue Y: The relationship between plasma high density lipoprotein cholesterol levels and cholesteryl ester transfer protein activity in six species of healthy experimental animals. Biol Pharm Bull 2001;24:579-581.
31. Wasan KM, Subramanian R, Kwong M, Goldberg IJ, Wright T, Johnston TP: Poloxamer 407-mediated alterations in the activities of enzymes regulating lipid metabolism in rats. J Pharm Pharm Sci 2003;6:189-197.